{"entity":{"id":"shin-sang-joon","kind":"person","name":"Sang Joon Shin","aka":[],"tldr":"Sang Joon Shin is a Yonsei medical oncologist active in colorectal cancer and melanoma immunotherapy trials.","summary":"Sang Joon Shin is Professor of Medical Oncology at Severance Hospital, Yonsei University, in Seoul, specialising in colorectal cancer and melanoma. He leads colorectal and melanoma research at Yonsei Cancer Center and is active in immunotherapy trials in both diseases. He has held investigator roles in studies of KRAS G12C inhibitors, anti-EGFR antibodies and checkpoint inhibitors, bringing Korean patients into these programmes. His interests are colorectal cancer, melanoma, immunotherapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shin%20SJ%5BAuthor%5D%20Yonsei%20colorectal%20melanoma"}],"tags":[],"related":[],"cancers":["colorectal","melanoma"],"sections":[],"technologies":[],"targets":["kras"],"drugs":[],"companies":[],"institutions":["severance"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; colorectal cancer and melanoma","institutionId":"severance","specialisms":["Colorectal cancer","Melanoma","Immunotherapy","Clinical trials"],"profiles":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shin%20SJ%5BAuthor%5D%20Yonsei%20colorectal%20melanoma"}],"papers":[{"title":"Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers","journal":"British Journal of Cancer","year":2016,"doi":"10.1038/bjc.2016.161"},{"title":"YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma","journal":"Cancer Immunology Research","year":2018,"doi":"10.1158/2326-6066.cir-17-0320"},{"title":"Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort","journal":"Cancer Research and Treatment","year":2017,"doi":"10.4143/crt.2016.024"},{"title":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2312117","doi":"10.1056/NEJMoa2312117"}]},"route":"/people/shin-sang-joon/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"institution":[{"id":"severance","kind":"institution","name":"Severance Hospital, Yonsei University","route":"/institutions/severance/"}],"paper":[{"id":"paper-ev-302-nejm-2024","kind":"paper","name":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","route":"/key-papers/paper-ev-302-nejm-2024/"}]}}